Sunovion Pharmaceuticals has acquired Cynapsus Therapeutics for $624 million, a deal that reflects Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology. Sunovion gets Cynapsus’ product candidate, APL-130277, which is designed to be a fast-acting, easy-to-use, on-demand treatment option for managing OFF episodes associated with Parkinson’s disease (PD). “Parkinson’s disease is a chronic, progressive neurodegenerative disease that aff...